RBC Bioscience

RBC Bioscience Net Tangible Assets

The Net Tangible Assets of RBC Bioscience (6848.TWO) as of Nov 7, 2026 is 236.43 M TWD. In the previous year, Net Tangible Assets was 237.57 M TWD — a change of -0.48% (lower).

Net Tangible Assets

236.43 MTWD

YoY

-0.48%

Last updated:

Net Tangible Assets of RBC Bioscience is 2024 236.43 M TWD. Net Tangible Assets of RBC Bioscience was 2023 237.57 M TWD. It decreases by -0.48% lower compared to the previous year.

The RBC Bioscience Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
81.22 M TWD
Jan 1, 2019
83.77 M TWD
Jan 1, 2020
171.19 M TWD
Jan 1, 2021
253.66 M TWD
Jan 1, 2022
246.36 M TWD
Jan 1, 2023
237.57 M TWD
Jan 1, 2024
236.43 M TWD
The RBC Bioscience Net Tangible Assets history
YEARNet Tangible AssetsYoY
236.43 MTWD-0.48%
237.57 MTWD-3.57%
246.36 MTWD-2.88%
253.66 MTWD+48.17%
171.19 MTWD+104.37%
83.77 MTWD+3.14%
81.22 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Net Tangible Assets of RBC Bioscience is 236.43 M TWD in 2024.

Net Tangible Assets of RBC Bioscience changed from 237.57 M TWD to 236.43 M TWD, representing a -0.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's RBC Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — RBC Bioscience

All Key Metrics — RBC Bioscience